2025 Semi-Annual Performance Forecast Current Period Performance Estimate The company anticipates continued losses for the first half of 2025, with net profit attributable to shareholders projected to be a loss of CNY 26 million to CNY 40 million, significantly narrowed from CNY 69.3855 million in the prior year period 2025 Semi-Annual Performance Forecast Details | Item | Current Reporting Period | Prior Year Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | Loss: CNY 26 million - CNY 40 million | Loss: CNY 69.3855 million | | Net Profit After Non-Recurring Items | Loss: CNY 20 million - CNY 34 million | Loss: CNY 67.5425 million | | Basic Earnings Per Share | Loss: CNY 0.0332/share - CNY 0.0510/share | Loss: CNY 0.0885/share | Communication with Accounting Firm The company explicitly states that the performance forecast data released has not been pre-audited by an accounting firm - This performance forecast has not been pre-audited by an accounting firm4 Explanation of Performance Changes The narrowed loss for the current period is primarily due to the positive contribution from the newly acquired biopharmaceutical business and the company's effective implementation of refined management and cost reduction measures - In January 2025, the company completed a cross-industry asset acquisition in the biopharmaceutical sector, with the new business segment performing well and positively impacting company performance5 - During the reporting period, the company successfully reduced overall management costs by optimizing internal management processes and implementing refined management measures such as cost control and expense reduction6 Other Relevant Information The company states this performance forecast is a preliminary estimate by the finance department, with final accurate financial data to be disclosed in the 2025 semi-annual report, advising investors to exercise caution - This performance forecast is a preliminary estimate by the company's finance department; specific financial data will be detailed in the 2025 semi-annual report, and investors are advised to be aware of investment risks7
惠程科技(002168) - 2025 Q2 - 季度业绩预告